LON:VRCI Verici Dx (VRCI) Share Price, News & Analysis GBX 0.38 +0.00 (+0.80%) As of 06/19/2026 11:14 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsBuy This Stock About Verici Dx Stock (LON:VRCI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Verici Dx alerts:Sign Up Key Stats Today's Range 0.35▼ 0.3850-Day Range 0.35▼ 0.5252-Week Range 0.35▼ 1.50Volume1.04 million shsAverage Volume1.75 million shsMarket Capitalization£5.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners. The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant. Read More Receive VRCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verici Dx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRCI Stock News HeadlinesVerici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026June 17 at 3:59 PM | finance.yahoo.comVerici Dx calls shareholder meeting to approve new share issuance after fundraisingJune 8, 2026 | tipranks.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.June 20 at 1:00 AM | Chaikin Analytics (Ad)Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant RecipientsMay 19, 2026 | finance.yahoo.comVerici Dx Launches Board Search After Non-Executive Director ResignsMarch 31, 2026 | tipranks.comVerici Dx Appoints Aubrey Powell as Non-executive DirectorOctober 6, 2025 | tipranks.comVerici Dx Reports First Revenues and Expansion Plans for 2025September 30, 2025 | msn.comVerici Dx plans shareholder meeting to approve new share issueMay 10, 2025 | investing.comSee More Headlines VRCI Stock Analysis - Frequently Asked Questions How have VRCI shares performed this year? Verici Dx's stock was trading at GBX 0.75 at the beginning of 2026. Since then, VRCI shares have decreased by 49.6% and is now trading at GBX 0.38. How do I buy shares of Verici Dx? Shares of VRCI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Verici Dx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verici Dx investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Bank of America (BAC) and Cal-Maine Foods (CALM). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:VRCI CIKN/A Webwww.vericidx.com Phone44 207 9338780FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (2.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£6.56 million Net Margins-468.31% Pretax MarginN/A Return on Equity-178.37% Return on Assets-26.14% Debt Debt-to-Equity Ratio11.36 Current Ratio0.91 Quick Ratio8.49 Sales & Book Value Annual Sales£1.91 million Price / Sales2.99 Cash FlowGBX 0.29 per share Price / Cash Flow1.31 Book ValueGBX 4.43 per share Price / Book0.09Miscellaneous Outstanding Shares1,513,394,000Free FloatN/AMarket Cap£5.72 million OptionableNot Optionable Beta1.26 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (LON:VRCI) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredAn Elon Musk Fan's Warning About SPCXJon Najarian called Tesla in 2014 when legacy automakers dismissed it. Now he's warning investors to skip SPCX...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verici Dx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verici Dx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
